SBPH Spring Bank Pharmaceuticals, In

+0  (2%)
Previous Close 9.05
Open 9.16
Price To book 5.01
Market Cap 86.63M
Shares 9,416,000
Volume 5,618
Short Ratio 1.66
Av. Daily Volume 19,363

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due 2Q 2017.
SB 9200
Hepatitis B (HBV)
Phase 2 to be initated pending funding.
SB 9200
Respiratory syncytial virus (RSV)

Latest News

  1. Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial and Operational Results
  2. ETFs with exposure to Spring Bank Pharmaceuticals, Inc. : April 21, 2017
  3. Spring Bank Pharmaceuticals, Inc. :SBPH-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  4. SBPH: 2016 Results Sustaining Continued HBV/STING Development
  5. Spring Bank Pharmaceuticals to Present Results from In Vivo Studies of SB 11285, a Novel STING agonist for Immuno-Oncology, at Keystone Symposia
  6. Spring Bank Pharmaceuticals Provides Corporate Update and Reports 2016 Financial and Operational Results
  7. Spring Bank Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference in NYC on February 16
  8. Spring Bank Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference in NYC
  9. Spring Bank Pharmaceuticals Inc (SBPH) An Ace Up Gilead Sciences, Inc. (GILD)’s Sleeve
  10. Spring Bank (SBPH) Inks 3rd Collaboration Agreement
  11. SBPH: Third Quarter has a Sting to it
  12. Arrowhead Partners with Spring Bank (ARWR, SBPH)
  13. Arrowhead Pharmaceuticals Inc. (ARWR), Spring Bank Pharmaceuticals, Inc. (SBPH) Collaborate On HBV
  14. Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B
  15. Hep B: Large Market and Dominant Pricing Potential; Initiating SBPH with $33.00 Target.